drugset / Trial / NCT04266509

Study to Evaluate the Effect of Repeat-Dose Rifampin on the Pharmacokinetics (PK) of PF-06651600

NCT04266509

Phase 1 Completed 12 enrolled Pfizer
RandomizedSequentialOpen-labelBasic science

Summary

Study to Evaluate the Effect of Repeat-Dose Rifampin on the pharmacokinetics (PK) of PF-06651600.

Timeline

Start
2020-06-25
Primary completion
2020-09-10
Completion
2020-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritlecitinib Small molecule 50 mg Oral
Background Rifampin Small molecule 600 mg

Indications

No indication recorded.